Ranbaxy Files For U.S. Generic Approvals Without FDA-Approved Pill Plant
This article was originally published in PharmAsia News
Executive Summary
Ranbaxy Laboratories, which has no U.S. FDA-approved production plant in India, nevertheless has filed to market its generic drugs in the U.S. from its research-and-development facility at Gurgaon.